|
Jul 26
|
Stocks to Watch Friday: DexCom, 3M, Coinbase, Charter
|
|
Jul 26
|
Bristol Myers Squibb Reports Second Quarter Financial Results for 2024
|
|
Jul 25
|
June PCE, Bristol Myers Squibb earnings: What to watch Friday
|
|
Jun 18
|
Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors
|
|
Jun 18
|
Bristol Myers Squibb Announces Dividend
|
|
Jun 13
|
U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
|
|
Apr 21
|
Is Bristol-Myers Squibb (NYSE:BMY) Using Too Much Debt?
|
|
Apr 15
|
In the wake of Bristol-Myers Squibb Company's (NYSE:BMY) latest US$5.7b market cap drop, institutional owners may be forced to take severe actions
|
|
Jan 2
|
European Medicines Agency Validates Bristol Myers Squibb’s Application for Repotrectinib for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer and NTRK-Positive Solid Tumors
|
|
Dec 27
|
A Tale of Two Pharmas: Can Obesity Firms Continue Their Outperformance in 2024?
|
|
Dec 27
|
Trending tickers: Intel | Tencent | RayzeBio | Astrazeneca
|
|
Dec 26
|
Bristol Myers buying RayzeBio, FedEx buyback: Trending tickers
|
|
Dec 26
|
Bristol-Myers Squibb to Buy RayzeBio for $4.1 Billion
|
|
Dec 22
|
Rocket Lab, Coinbase, Bristol Myers-Karuna deal: Trending tickers
|
|
Dec 22
|
Bristol Myers acquiring Karuna Therapeutics in $14B deal
|
|
Dec 22
|
Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
|
|
Dec 22
|
Bristol Myers Squibb to Present at J.P. Morgan’s 42nd Annual Healthcare Conference
|
|
Dec 22
|
Bristol Myers to Buy Karuna Therapeutics for $14 Billion
|
|
Dec 20
|
Bristol Myers Squibb to Participate in the 2024 Goldman Sachs Healthcare C-Suite Unscripted Conference
|
|
Dec 15
|
Bristol Myers Squibb to Discontinue Metastatic Colorectal Cancer Trial
|